BAMF
KRYS icon

BI Asset Management Fondsmaeglerselskab’s Krystal Biotech KRYS Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-408
Closed -$74K – 837
2025
Q1 		$74K Buy
+408
New +$68.6K ﹤0.01% 727

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's KRYS Position: Q2 2025 in Review

BI Asset Management Fondsmaeglerselskab sold out of Krystal Biotech (KRYS) in Q2 2025, closing a stake of 408 shares — an estimated $74K sold.

BI Asset Management Fondsmaeglerselskab first reported a position in KRYS in Q1 2025 and held it in 1 quarter. The position peaked at $74K in Q1 2025. 275 funds tracked by Wall St. Rank hold KRYS as of Q2 2025.

  • BI Asset Management Fondsmaeglerselskab reported no remaining Krystal Biotech position as of Q2 2025 after selling out during the quarter.
  • BI Asset Management Fondsmaeglerselskab sold 408 Krystal Biotech shares in Q2 2025, an estimated $74K.
  • BI Asset Management Fondsmaeglerselskab first reported a position in Krystal Biotech in Q1 2025 and held it in 1 quarter.
  • BI Asset Management Fondsmaeglerselskab's Krystal Biotech position peaked at $74K in Q1 2025.
  • 275 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2025.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q2 2025, filed 14 Aug 2025.